Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 10, 2011, Pages 1271-1278

  Hsu, M S ^a   Liao, C H ^a   Huang, Y T ^b   Liu, C Y ^a   Yang, C J ^a   Kao, K L ^a   Hsueh, P R ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TIMENTIN;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CATHETER INFECTION; CHRYSEOBACTERIUM MENINGOSEPTICUM; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; PRIMARY INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; TAIWAN;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; CHRYSEOBACTERIUM; CROSS INFECTION; DIABETES COMPLICATIONS; FEMALE; FLAVOBACTERIACEAE INFECTIONS; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054724488     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1223-0     Document Type: Article

References (24)

1. P Vandamme JF Bernardet P Segers, et al. 1994 New perspectives in the classification of the flavobacteria: description of Chryseobacterium gen. nov., Bergeyella gen. nov., and Empedobacter nom. Rev Int J Syst Bacteriol 44 827 831 10.1099/00207713-44-4-827
2. Schreckenberger PC (2003) Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds) Manual of clinical microbiology, 8th edn. American Society for Microbiology, Washington, DC, pp 749-779
3. KK Kim MK Kim JH Lim 2005 Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov Int J Syst Evol Microbiol 55 1287 1293 15879269 10.1099/ijs.0.63541-0 1:CAS:528: DC%2BD2MXltlOlsrc%3D
4. S Gungor M Ozen A Akinci, et al. 2003 A Chryseobacterium menigosepticum outbreak in a neonatal ward Infect Control Hosp Epidemiol 24 613 617 12940584 10.1086/502261
5. MS Tekerekoglu R Durnaz M Ayan, et al. 2003 Analysis of an outbreak due to Chryseobacterium meningosepticum in a neonatal intensive care unit New Microbiol 26 57 63 12578312 1:STN:280:DC%2BD3s%2FmslOhsg%3D%3D
6. SK Spangler MA Visalli MR Jacobs, et al. 1996 Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem Anitmicrob Agents Chemother 40 772 775 1:STN:280:DyaK2s%2FgsVaqug%3D%3D
7. SL Fraser JH Jorgensen 1997 Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing Anitmicrob Agents Chemother 41 2738 2741 1:CAS:528:DyaK2sXnvFWjsLk%3D
8. E Yabuuchi T Kaneko I Yano, et al. 1983 Sphingobacterieum gen. nov., Sphingobacterium spiritivorum comb. nov., Sphingobacterium mizutae sp. nov., and Flavobacterium indologenes sp. nov.: glucose-nonfermenting, gram-negative rods in CDC group like-2 and IIb Int J Syst Bacteriol 33 580 598 10.1099/00207713-33- 3-580
9. Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100-S20. CLSI, Wayne, PA, USA, 2010
10. JS Garner WR Jarvis TG Emori, et al. 1988 CDC definition for nosocomial infections, 1988 Am J Infect Control 16 128 140 2841893 10.1016/0196-6553(88) 90053-3 1:STN:280:DyaL1czgvVSnug%3D%3D
11. CH Liao WH Sheng YC Chen, et al. 2007 Predictive value of the serum bactericidal test for mortality in patients infected with multidrug-resistant Acinetobacter baumannii J Infect 55 149 157 17376533 10.1016/j.jinf.2007.01.015
12. Y Carmeli M Akova G Cornaglia, et al. 2010 Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control Clin Microbiol Infect 16 102 111 20085604 10.1111/j.1469-0691.2009. 03115.x 1:CAS:528:DC%2BC3cXitlKqt70%3D
13. HS Sader RN Jones 2005 Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli Int J Antimicrob Agents 25 95 109 15664479 10.1016/j.ijantimicag.2004.10.002 1:CAS:528:DC%2BD2MXms1Ojuw%3D%3D
14. JT Kirby HS Sader TR Walsh, et al. 2004 Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp report from the SENTRY Antimicrobial Surveillance Program (1997-2001) J Clin Microbiol 42 445 448 14715802 10.1128/JCM.42.1.445-448.2004 1:CAS:528:DC%2BD2cXht1Wnuro%3D
15. CH Chiu M Waddingdon WS Hsieh, et al. 2000 Atypical Chryseobacterium meningosepticum and meningitis and sepsis in newborns and the immunocompromised, Taiwan Emerg Infect Dis 6 481 486 10998378 10.3201/eid0605.000506 1:CAS:528:DC%2BD3cXns1KnsL4%3D
16. KC Bloch R Nadarajah R Jacobs 1997 Chryseobacterium meningoseptiucm: an emerging pathogen among immunocompromised adults Medicine 76 30 41 9064486 10.1097/00005792-199701000-00003 1:STN:280:DyaK2s7ovV2guw%3D%3D
17. PY Lin C Chu LH Su, et al. 2004 Clinical and microbiological analysis of bloodstream infections caused by Chryseobacterium meningosepticum in nonneonatal patients J Clin Microbiol 42 3353 3355 15243115 10.1128/JCM.42.7.3353-3355.2004
18. J Fujita Y Hata S Irino 1990 Respiratory infection caused by Flaveobacterium meningosepticum Lancet 335 544 1968556 10.1016/0140-6736(90) 90780-9 1:STN:280:DyaK3c7ntlGktA%3D%3D
19. BE Hirsh B Wong TE Kiehn, et al. 1989 Flavobacterium meningoseptiucm bacteremia in an adult with acute leukemia. Use of rifampin to clear persistent infection Diagn Microbiol Infect Dis 4 65 69 10.1016/0732-8893(86)90058-1
20. PP Hung YH Lin CF Lin, et al. 2008 Chryseobacterium meningosepticum infection: antibiotic susceptibility and risk factors for mortality J Microbiol Immunol Infect 41 137 144 18473101
21. M Pokrywka K Viazanko J Medvick, et al. 1993 A Flavobacterium meningosepticum outbreak among intensive care patients Am J Infect Control 21 139 145 8342868 10.1016/0196-6553(93)90005-O 1:STN:280:DyaK3szktlGhuw%3D%3D
22. YT Lin YJ Chan CH Chiu, et al. 2009 Tigecycline and colistin susceptibility of Chryseobacterium meningsepticum isolated from blood in Taiwan Int J Antimicrob Agents 34 99 102 10.1016/j.ijantimicag.2009.01.011
23. H Wisplinghoff T Bischoff SM Tallent, et al. 2004 Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 309 317 15306996 10.1086/421946
24. EJ Giamarellos-Bourboulis L Karnesis I Galani, et al. 2002 In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole Antimicrob Agents Chemother 46 3997 3999 12435710 10.1128/AAC.46.12.3997-3999.2002 1:CAS:528:DC%2BD38XptVynurg%3D